W e have previously shown that the chimeric gene ABL-BCR, formed on the derivative chromosome 9q + as a result of the t(9;22) translocation, is transcriptionally active in 65% of chronic myeloid leukemia patients. W e have now used the same technique, reverse transcription/polymerase chain reaction amplification of ABL-BCR transcripts, to study nine patients with Philadelphia (Ph) chromosome-positive acute lymphoblastic leukemia (ALL); seven expressed the P190 and two the P210 type of BCR-ABLfusion protein. All seven patients with P I 90 had ABL-BCR transcripts containing a HE RECIPROCAL translocation t(9;22)(q34; q l 1) that T produces the Philadelphia (Ph) chromosome characteristic of chronic myeloid leukemia (CML) is also found in 2% to 10% of children and 20% to 55% of adults with acute lymphoblastic leukemia (ALL). The Ph chromosome carries a hybrid BCR-ABL gene thought to be central to the malignant process. In CML and in approximately 30% of Ph+ ALLs, the break in the BCR gene occurs in the major breakpoint cluster region (M-bcr), and the BCR-ABL mRNA transcripts are formed by the junction of BCR exons b2 and/ or b3 to ABL exon 2 (b2a2 and b3a2, respectively). This results in a BCR-ABL protein of 210 Kd molecular weight (P210). In the remaining 70% of Ph+ ALL patients, the breakpoints on chromosome 22 are more 5' and cluster within the long first intron of the BCR gene, designated minor bcr (m-bcr). In these cases, only the first BCR exon is fused to ABL exon 2 (ela2 junction), and a smaller BCR-ABL protein of 190 Kd (P190) is formed.
T produces the Philadelphia (Ph) chromosome characteristic of chronic myeloid leukemia (CML) is also found in 2% to 10% of children and 20% to 55% of adults with acute lymphoblastic leukemia (ALL). The Ph chromosome carries a hybrid BCR-ABL gene thought to be central to the malignant process. In CML and in approximately 30% of Ph+ ALLs, the break in the BCR gene occurs in the major breakpoint cluster region (M-bcr), and the BCR-ABL mRNA transcripts are formed by the junction of BCR exons b2 and/ or b3 to ABL exon 2 (b2a2 and b3a2, respectively). This results in a BCR-ABL protein of 210 Kd molecular weight (P210). In the remaining 70% of Ph+ ALL patients, the breakpoints on chromosome 22 are more 5' and cluster within the long first intron of the BCR gene, designated minor bcr (m-bcr). In these cases, only the first BCR exon is fused to ABL exon 2 (ela2 junction), and a smaller BCR-ABL protein of 190 Kd (P190) is formed.
Because the t(9;22) is a reciprocal event, it could give rise to a second fusion gene, ABL-BCR, on the derivative 9q+. Such a gene should encode a protein containing the N-terminal ABL and C-terminal BCR domains that are absent from BCR-ABL, in a novel and perhaps functional fusion rearrangement. We have recently shown that the ABL-BCR fusion gene is in fact formed and transcribed in approximately two-thirds of CML patients3 We report here that ABL-BCR is also expressed in Ph+ ALL, and could encode fusion proteins with different functional domains depending on the breakpoint location in BCR. 
MATERIALS AND METHODS
Nine consecutive adult patients with Ph+ ALL were identified from a larger series of acute leukemias on the basis of cytogenetics and molecular criteria (Tuszynski et al, manuscript submitted). Eight patients were studied at diagnosis and one at relapse after chemotherapy. The leukemic cells were CALLA+ in 8 cases, but blast cells from one patient had a ''null" phenotype. The mean absolute blast count in this series was 48.4 X 109/L, with a range of 1.9 to 138.6 X 1 09/L. Seven patients expressed PI 90BCR-ABL protein and two expressed P2 IOBCR-ABL, as detected in in vitro kinase assays? Two Ph+ CML patients with known BCR-ABL and ABL-BCR transcript types3 were also included for comparison with the ALL samples.
SDI is a lymphoblastoid cell line established by Epstein-Barr virus (EBV) immortalization of Phf PI 90 ALL cells from one of the patients studied in the present series.' The HL60 promyelocytic cell line was used as a negative control for BCR-ABL and ABL-BCR expression.
Peripheral blood mononuclear cells were isolated by Ficoll-Hypaque density-gradient centrifugation and used for RNA extraction. Amplification of specific sequences on the ABL, BCR, BCR-ABL, and ABL-BCR genes was performed by reverse transcription (RT) of oligo-dT-primed cDNA, followed by PCR (RT/PCR) exactly as described previo~s l y .~ The synthetic oligonucleotides used for PCR amplification were: the primers PAa+, Ab+, Jc-, BI +, B4-, and G-, described previously3; two new BCR primers, BAL+ (in exon el) (5')GAACTCGCAACAGTCCTTCGAC(3') and BE2-(in exon e2) (5')AGGTAgaTCTCCTCGCTAGCCAGGATT(3' ); and one new ABL primer, GLY+ (in exon Ib) (5')GGGCAGCAGCCTG-GAAAAG(3'). The relative positions of primers on BCR and ABL sequences are shown on Fig 1. Each PCR experiment was repeated at least once and included two negative controls (HL60 cDNA and no cDNA template). Further precautions towards eliminating the possibility of false PCR results were described el~ewhere.~ Direct sequencing of PCR products was performed by the Tag cycle sequencing method (US Biochemicals, Cleveland, OH).
Patients and cell lines.
Polymerase chain reaction (PCR) amplification.
RESULTS
Expression of the normal ABL and the normal BCR genes was detected in all nine ALL cases and in the SDI cell line by means of PCR amplification with the PAa' c* Jc-(384 bp), Ab+ -Jc-(462 bp), and B1' f-* G-(1,208 bp) primer PCR amplification with primers BAL+ and Jc-showed BCR-ABL transcripts of 463 bp, corresponding to a ela2 junction, in the seven P190BCR-ABL samples and in the SDl cell line (Fig 2A, lanes 2 through 9) . The two P210BCR-ABL pairs. 
E-
ALL samples did not yield detectable PCR products with these primers, but showed positive amplifications with primers BI + and Jc-; one sample exhibited a b3a2 junction type and in the other an exceptionally small BCR-ABL product was detected (Fig 2A, lanes 12 and 13, respectively) . Sequencing of the latter showed that the BCR-ABL junction in this sample was between BCR exon b2 and ABL exon 3 (b2a3).
Expression of the reciprocal ABL-BCR fusion gene was investigated by PCR amplification of fragments encompassing ABL exons Ib or la, and BCR sequences downstream of exon el, as predicted from the breakpoint sites in ABL and BCR, respectively. By using primers GLY+ and BE2-, PCR products 404-bp long were detected in all seven P190BCR-ABL ALL samples ( Fig 2B, lanes 2 through 8) , characterizing an b e 2 junction in these cases. Amplifications spanning ABL-BCR sequences between primers PAa' and BE2-showed transcripts of the Ia-e2 type in only two of the seven PI90 ALL samples. The SDI cell line exhibited no ABL-BCR expression (Fig 2B, lane 9) .
As expected, no ABL-BCR amplification was observed with either primer pair in the two ALL cases with a P2 IOBCR-ABL product, because the breakpoint in these cases occurs in the M-bcr region. Nevertheless, PCR tests with primers used for identifying ABL-BCR message in CML (Ab+ * G -and PAa+ -G -) showed amplification of the I b b 4 transcript type in one sample, but no ABL-BCR product in the other (Fig 2B,  lanes 12 and 13, respectively) . Table I summarizes the overall results on BCR-ABL and ABL-BCR expression in this series. These results were further verified by amplification of a larger ABL-BCR fragment in reactions primed with the oligonucleotides Ab' and B4-; a 1,774-bp product ( b e 2 junction) was detected in all seven PI90 ALL samples, whereas the P210 ALL sample with Ibb4 junction showed a 297-bp long fragment. Again, there was no evidence of ABL-BCR expression in the SD 1 cell line and in the second P2 IO ALL patient.
Direct sequencing of the I k 2 and Iae2 PCR products fiom one representative PI90 ALL patient showed that the junction between SABL and 3'BCR sequences was in frame with the initiation codons of ABL exons Ib and Ia, respectively.
DISCUSSION
We have recently shown that the ABL-BCR fusion gene, the reciprocal partner of the Ph chromosome BCR-ABL gene, is expressed in two-thirds of CML patients.' This finding prompted us to investigate whether the same phenomenon -8f2-(lanes 2 through 10) and Ab+ -G -(lanes 12 through 16) Patients n = 7 P190 ela2 lb-e2
Abbreviation: ND, not detected.
occurs in Ph+ ALL. By means of single-step RT/PCR amplifications, we detected ABL-BCR transcripts with an ib-e2 junction in all seven P1908CR-ABL patients tested in the present study. Only two of seven samples expressed ABL-BCR messages derived from both ABL first alternative exons Ib and Ia (Ib-e2 and la-e2), suggesting that, as in CML, the frequency of breakpoints between exons Ib and la is significantly higher than that between exons la and 11. On the other hand, formation and expression of the ABL-BCR gene may be more common in P 190 ALL (1 00% in this series) than in CML (70'70),~ although the number of samples we tested is small. If confirmed in a larger series, this finding suggests that events that in 30% of CMLs preclude the formation of an intact ABL-BCR gene, such as breakpoints in chromosome 9 upstream of exon Ib6 or deletions of 3' BCR sequence^,^ are extremely rare in P190 ALL. The SD1 cell line did not express any ABL-BCR product, although this line carries the 9q+ derivative chrom~some.~ In contrast, the patient's cells from which the SDl cell line was derived were found to express the ABL-BCR gene. This disparity is not readily explained, but immortalization with EBV could have acted to downregulate ABL-BCR expression.
ABL-BCR expression can also be found in Ph+ ALL of the P210 type, as exemplified by the detection of an Ib-M transcript type in one of the two samples tested here. The other P2 10 ALL studied has an unusual, albeit not unprecedented,8,9 BCR-ABL transcript in which ABL exon 3, rather than 2, is fused to BCR exon b2 (b2a3 junction). The reciprocal ABL-BCR message in this case should be longer, with ABL exon 2 joined in phase to BCR exon b3 (a2b3). In practice, no ABLBCR transcript was detected in this case, despite repeated studies with various primer pairs (data not shown). The mechanism accounting for the absence of ABL-BCR expression in this case could be the same as for the one-third of CML patients who are ABL-BCR negative, as discussed above and el~ewhere.~
The predicted coding sequences of the ABL-BCR proteins in P190 ALL are in frame, as they are in CML and in P210 ALL, with ABL contributing the first base and BCR the second and third bases of the junction codon. It is interesting that this junction codon is an aspartic acid in all the 6 possible types of ABL-BCR junction observed so far (ie, Ib-b3,Ia-b3, Ib-b4, Ia-b4 in CML and P2 10 ALL, and Ib-e2 and Ia-e2 in Pi90 ALL).
The open reading frame of the ABL-BCR hybrid cDNAs from P190 ALL predicts fusion proteins of 890 (Ib-e2) and 871 (la-e2) amino acids, which are more than double the size of the predicted ABL-BCR gene products of CML and P2 10 ALL.3 In all cases the ABL-BCR proteins would contain the C-terminal GAPruc coding domain of BCR." However, another domain recently identified on the BCR gene with homology to the dbl oncogene, the VAV proto-oncogene and the yeast CDC24 gene,'',j2 would be variably located in the BCR-ABL and the ABL-BCR fusion proteins of P210 and P190 Ph+ leukemias. Thus, breakpoints in M-bcr (CML and P210 ALL) lead to inclusion of the dbl-like domain in the BCR-ABL protein, whereas breakpoints in m-bcr (P190 ALL) result in this domain being included in the predicted reciprocal ABL-BCR, instead of the BCR-ABL fusion product. The dbl-like domain encodes a GDP-GTP exchange factor for the RAS-like polypeptide CDC42Hs," which suggests that BCR may function through the regulation ofa RAS-like signal transduction pathway.12 It has been proposed that the contribution of the exchange factor domain to P210 but not P190 may explain the qualitative biologic differences between these two forms of BCR-ABL protein." Conversely, it is conceivable that the presence or absence of the dbl-like domain in the putative reciprocal ABL-BCR protein will dictate its functional relevance. For personal use only. on November 16, 2017. by guest www.bloodjournal.org From
